Contribute Try STAT+ Today

Hello, everyone, and how are you this morning? We are doing just fine, thank you. And why not? The Pharmalot campus is blessed with a warm and shiny sun, a clear blue sky, and a deliciously cool breeze. Not to mention a functioning coffee kettle for brewing hot cups of stimulation. Of course, while we enjoy these gifts, we are also foraging for items of interest, some of which you can find below. We hope these help you on your journey today and you conquer the world. Meanwhile, please do stay in touch …

Louisiana and Gilead Sciences (GILD) are working on a deal to change how the state pays for hepatitis C drugs, NPR tells us. The idea is a subscription, or the Netflix (NFLX) model — the state would agree to pay a fixed amount of money over several years and, in turn, the drug maker would provide all the medication that is needed. Initially, Louisiana would get more drug than it would pay for, but in later years, Gilead would get extra money. “Ideally, we would have something in place this year,” says Gregg Alton, executive vice president of corporate and medical affairs at Gilead.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.